Great to see more success in a trial to aim for less radical options for those with low risk diagnosis
http://www.globenewswire.com/news-release/2018/01/22/1298621/0/en/Nymox-Reports-5-Year-Results-From-Prospective-Randomized-Controlled-Prostate-Cancer-Study-of-Fexapotide-Triflutate-in-146-U-S-Men.html